SCHEMBL24309950

SCHEMBL24309950

CCOc1ccccc1-c1nc(NS(=O)(=O)c2cnn(Cc3ccccc3)c2)nc(Oc2cccc(N3CCN(C)CC3)c2Cl)c1CC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAK1 Q13153 2/20 0.36
▸ EGFR P00533 2/20 0.35
▸ DRD2 P14416 4/20 0.35
▸ DRD4 P21917 3/20 0.35
▸ DRD3 P35462 3/20 0.35
▸ HCRTR1 O43613 1/20 0.34
▸ DRD1 P21728 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ TP53 P04637 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ CFTR P13569 1/20 0.33
▸ TNK2 Q07912 1/20 0.33
▸ HTR1A P08908 3/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ ADRA1D P25100 1/20 0.33
▸ ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567289 1.00 PAK1 (0.36) PAK1EGFRDRD2DRD4DRD3
SCHEMBL24309428 0.94 EGFR (0.32) PAK1EGFRDRD2DRD4DRD3
SCHEMBL29566832 0.94 EGFR (0.32) PAK1EGFRDRD2DRD4DRD3
SCHEMBL24309904 0.93 HTR1A (0.33) PAK1EGFRDRD2DRD4DRD3
SCHEMBL29567063 0.92 EGFR (0.36) EGFRDRD2DRD4DRD3TNK2
SCHEMBL24309999 0.92 EGFR (0.36) EGFRDRD2DRD4DRD3TNK2
SCHEMBL29566593 0.92 DRD2 (0.36) PAK1DRD2DRD4DRD3CFTR
SCHEMBL24310048 0.92 HTR1A (0.38) PAK1EGFRDRD2DRD4DRD3
SCHEMBL24309884 0.92 DRD2 (0.36) PAK1DRD2DRD4DRD3CFTR
SCHEMBL29566746 0.92 HTR1A (0.38) PAK1EGFRDRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B PAK1 2740/4885EGFR 818/4885DRD2 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback